Grebe 1998.

Methods	Method of randomisation: No description given Assessor blinding: Not mentioned Intention‐to‐treat: Yes
Participants	Location: Wellington Hospital, New Zealand Period of study: Before 1998 Participant description: Initial episode of Graves' disease. Diagnosis based on clinical grounds, thyroid function tests, Uniform uptake of 99m technetium scan. Inclusion criteria: Graves' disease as above Exclusion criteria: Known pituitary, liver or haematological abnormalities, pregnancy, known allergy to thionamides Sex: M/F: A: 5/12; B: 3/17 Age: mean (SD) A: 33(8.7); B: 33.7 (11.9) Baseline comparability: No statistically significant differences
Interventions	Description of intervention: A: Titration of carbimazole (Initial dose 25 mg daily) adjusted to maintain euthyroidism (mean dose carbimazole 17 mg/d) B: Block and replace; carbimazole 100 mg/d, thyroxine added after 2‐4 weeks to maintain euthyroidism
Outcomes	Main outcome: Relapse of hyperthyroidism
Study details	Duration of therapy: 6 months Allocated: A: 20; B: 17 Completed: A: 16; B: 9 Assessed: A: 16; B: 9 Length of follow‐up: 24 months
Publication details	Language of Publication: English Publication status: Peer reviewed journal
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Blinding? All outcomes	High risk
Incomplete outcome data addressed? All outcomes	Low risk